1977 ntis annual report: phase i clinical testing. antimalarial drugs. annual report
DESCRIPTION
1977 report about Phase I clinical trials of mefloquine and another antimalarial drug, written by Richard C. Reba, M.D.TRANSCRIPT
![Page 1: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/1.jpg)
ADA04/1243
PHASE I CLINICAL TESTING. ANTIMALARIALDRUGS
BIO-MED INC WASHINGTON DC
MAR 1976
Downloading.- --- --___
-----A
''..---- - ---' ------•---- -: 7; -- -. - ; -: : - -e- - -0::: - - -- -__ _ -- ' -- -:
0 - - -
One Source. One Search. One Solution.
U.S. Department of CommerceNational Technical Information Service
![Page 2: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/2.jpg)
One Source. One Search. One Solution.
Providing Permanent, Easy Accessto U.S. Government Information
The National Technical Information Service is theNation's largest repository and disseminator ofgovernment-initiated scientific, technical, engineering,and related business information. The NTIS collectionincludes almost 3 million information products in avariety of formats: electronic download, onlineaccess, DVD, CD-ROM, magnetic tape, diskette,multimedia, microfiche and paper.
Search the NTIS Database from 1990 forwardMore than 600,000 government research information products have been addedto the NTIS collection since 1990. All bibliographic entries for those products aresearchable on the NTIS Web site at www.ntis.gov.
Download Publications (1997 - Present)NTIS provides the full text of many reports received since 1997 as downloadablePDF files. When an agency stops maintaining a report on its Web site, NTIS stilloffers a downloadable version. There is a fee for each download of mostpublications.
For more information visit our website:
www.ntis.gov
OP
\ U.S. DEPARTMENT OF COMMERCE* Technology AdministrationAl National Technical Information Service
of Springfield, VA 22161
• r4
![Page 3: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/3.jpg)
REPORT NUMBER 1
Phase I C l i n i c a l Te s t i n gA n t i m a l a r i a l D r u g s
Annua l R e p o r t
R i c h a r d C . R e b a , M . D .
Date A u g u s t 1977
Suppo r ted b y
U.S. ARMY- M E D IC A L R ES EA RC H AND D EV EL OP ME NT COMMAND
Wa s h i n g t o n , D . C . 2 0 3 1 4
C o n t r a c t N o . DAMD 1 7 - 7 5 - C - 5 0 3 6
BIO-MED, I n c .110 I r v i n g S t r e e t , N . W.Wa s h i n g t o n , D . C . 2 0 0 1 0
Approved f o r p u b l i c r e l e a s e ;d i s t r i b u t i o n u n l i m i t e d
AD
The f i n d i n g s i n t h i s r e p o r t a r e n o t t o b e c o n s t r u e d a s a no f f i c i a l D e p a r t m e n t o f t h e A r m y p o s i t i o n u n l e s s s o d e s i g n a t e dby o t h e r a u t h o r i z e d d o c u m e n t s .
1
![Page 4: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/4.jpg)
S E C U R I T Y C L A S S I F I C AT I O N O F T H I S P A G E (When D a r n E n ( e r e d )
- R E P O R T DOCIJMENTATION PAGE R E A D I N S T R U C T I O N SB E F O R E C O M P L E T I N G F O R M
I . R E P O R T N U M B E R
1 •2. G O V T A C C E S S I O N N O . 3. R E C I P I E N T ' S C A T A L O G N U M B E R
-4,----Trf-t-e-ftertt.styl,turwy-.... ' --- ', - -- v r - r r p e - t r p . R E
Phase ' , C l i n i c a l T e s t i n g uA n t i m a l a r i a l D r u g s .
- _ — . . . . .0 E R I O D C O V E R E
Annual,,,R'epetx . ...-1/.."0-,Feb.:,' 1 .9 75 . te-Feb, )'976
A
-rt-rt-ATtyitor4tevilton,t-robwr l i ; u M E i-E 4 R ' ' Y ' '' '
7. A U T H O R ( s ) 8. C O N T R A C T O R G R A N T N U M B E R ( s )
17-75-C-5,636/,.,,..
)i M . D.i R i c h a r d C .
S. P E R F O R M I N G O R G A N I Z AT I O N N A M E A N D A D D R E S S
BIO-MED, I n c . , G e o r g e Hyman R e s e a r c h B l d g110 I r v i n g S t r e e t , N . W .Wa s h i n g t o n , D . C . 2 0 0 1 0 L ( 4 ,5, /
10. P R O G R A M E L E M E N T, PRJOLLECT, T A S KA R E A & W O R K U N I T Nfk r I p a•R S
,)(1./..
.31476277&8Y3 1PD I 005 'I L C O N T R O L L I N G O F F I C E N A M E A N D A D D R E S S
U.S. A r m y M e d i c a l R e s e a r c h a n d D e v e l o p m e n t j M a r q hCommand . 0Wa s h i n g t o n , D . C . 2 0 3 1 4
1 Z , - - ' R E_ 13' -0 ' I T T t r _ A ' ' rE
1976 •.1-3., A G E S
2014. M O N I T O R I N G A G E N C Y N A M E & A D D R E S S ( J 1 d i f f e r e n t f rom C o n t r o l l i n g O f f i c e )
. , IS. S E C U R I T Y C L A S S . ( o f t h i n r epo r t )
NoneISa. D E C L A S S I F I C A T I O N / D O W N G R A D I N G
S C H E D U L E N /A16. D I S T R I B U T I O N S T A T E M E N T ( o f t h i n R e p o r t )
Approved f o r p u b l i c r e l e a s e ;d i s t r i b u t i o n u n l i m i t e d
17. D I S T R I B U T I O N S T A T E M E N T ( o f t h e a b s t r a c t e n t e r e d in B l o c k 20, i f d i f f e r e n t f rom R e p o r t )
App roved f o r p u b l i c r e l e a s e ;d i s t r i b u t i o n u n l i m i t e d .
IS. S U P P L E M E N T A R Y N O T E S
_
A
19. K E Y W O R D S ( C o n t i n u e o n r e v e r n e o ic in i f n e c e s e a r y r e l d i d e n t i f y b y b l o c k number)
/
Phase I C l i n i c a l Te s t i n g , M e f l o q u i n e , A n t i m a l a r i a l D r u g s ,WR 184 ,806-H3PO4, Human S u b j e c t s11,.: 1,' ' , ' c A. c 0 5\ :- . --,,
20. A B S T R A C T (Con-f&q.. le o . , re vA;rDs ercbn f i ne-ceseary e n d i d e r r t i l y b y b l o c k number )
The r •-e p o rt i nc lu de s work performed under Contract
f r o p O ' e b r u a r y 1 9 7 5 t h r o u g h t h e f i r s t c o n t r a c t
r.1......... a n o t h e r q u i n o l i n e m e t h a n o l . , ,p06-H3t 'u4 /. i. L o c ,\, , . . 7 )
A c h r o n i c s a f e t y a n d t o l e r a n c e s t u d y o f m e f l o q u i n et e d , q n.w h i c h 5 0-' -s u b je c t s Will r ec ei ve .5 00
- .s
DAMT 1 7 - 7 5 - C - 5 0 3 6y e a r . T w o d r u g s h a v e
LL'-.. W O L
J a a s - - - 1 3 - --e n i n i t i a -
mg m e f l o q u i n e o r p l a c e b o ),z-,..---,,t / ,-.)., /,,, .,i---:i —
iD D Fic )„ , ,47-3 1473 EDITION OF 7 NOV 6S IS OaSOLETE
S E C U R I T Y C L A S S I F I C A T I O N O F T H I S P A G E (7Then B a t e E n t e r e
2
![Page 5: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/5.jpg)
20. A b s t r a c t ( C o n t i n u e d )
,,weekly for 52 weeks. Clinical, ophthalmologic, hematologic and biochemical
' m o n i t o r i n g a r e p e r f o r m e d s e r i a l l y . D u r i n g t h e i n i t i a l weeks o f s t u d y -comp l i ance h a s b e e n e x c e l l e n t a n d-n o a d v e r s e r e a c t i o n s h a v e b e e n o b s e r v ed .
S t u d i e s a r e a l s o a p p r o v e d t o d e t e r m i n e t h e t o p t o l e r a t e d s i n g l e o r a l d o s eo f m e f l o q u i n e a n d t h e s a f e t y a n d t o l e r a n c e o f m e f l o q u i n e when a d m i n -i s t r a t i o n o f a s i n g l e 4' t h e r a p e u t i c ' o r a l d o s e l e v el i s r e p e a t ed 4 s e v e n- ( 1 _ )
days a f t e r t h e f i r s t a d m i n s t r a t i o n .H
The f i r s t a d m i n i s t r a t i o n o f WR 1 8 4 1.8 0 6 - H3P O4 t o h u m a n s h a s b e e n
accomp l i shed . U s i n g d o u b l e - b l i n d r i s i n g d o s e l e v e l s i n g l e o r a l d o s e swere w e l l t o l e r a t e d t o t h e 1000 mg l e v e l ) s i x s u b j e c t s r e c e i v i n g 1200to 1 4 0 0 mg a l l d e v e l o p e d i n t o l e r a n c e m a n i f e s t e d b y c o m b i n a t i o n s o f l i g h t - •headedness w i t h a s s o c i a t e d d i f f i c u l t i e s s u c h a s c o n c e n t r a t i n g a n d f o c u s i n g ,headache, n a u s e a , i n s o m i a , a n d u rn Iquq , ,d reams . I n a l l s u b j e c t s t h esymptoms w e r e n o n - i n c a p a c i t a t i n g d h a i o f > l e s s t h a n 2 4 h o u r saL a u r a t i o n
' M u l t i p l e o r a l d o s e s w e r e t h e n t e s t e d a d m i n i s t e r i n g d r u g o r p l a c e b o e v e r y 'i g h t 2 h o u r s f o r 7 2 h o u r s . ( 9 d o s e s ) . ) I n t o l e r a n c e m a n i f e s t a t i o n s w e r e
s i m i l a r t o t h o s e o b s e r v e d i n t h e s i n g l e d o s e s t u d y a n d o c c u r r e d a t t h e3600 mg t o t a l d o s e l e v e l ( 4 0 0 m g / i n d i v i d u a l d o s e ) .
I t i s c o n c l u d e d t h a t t h e expanded s t u d i e s o f m e f l o q u i n e a r e o f v a l u e a n dshou ld b e c o n t i n u e d . W R 1 8 4 , 8 0 6 - H PO i s w e l l t o l e r a t e d a n d i n t o l e r a n c e3 4i s m a n i f e s t e d o n l y b y n o n - i n c a p a c i t a t i n g symptoms. P h a r m a c o k i n e t i cs t u d i e s a r e i n d i c a t e d a s a p r e l u d e t o Phase I I s t u d i e s .
![Page 6: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/6.jpg)
REPORT NUMBER 1
Phase I C l i n i c a l Te s t i n gA n t i m a l a r i a l D r u g s
Annua l R e p o r t
R i c h a r d C . R e b a , M . D .
Date A u g u s t 1 9 7 7
AD
• S u p p o r t e d b y
U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMANDWa s h i n g t o n , D . C . 2 0 3 1 4
C o n t r a c t N o . DAMD 1 7 - 7 5 - C - 5 0 3 6
BIO-MED, I n c .110 I r v i n g S t r e e t , N . W.Wa s h i n g t o n , D . C . 2 0 0 1 0
.Approved f o r p u b l i c r e l e a s e ;d i s t r i b u t i o n u n l i m i t e d
The f i n d i n g s i n t h i s r e p o r t a r e n o t t o b e c o n s t r u e d a s a no f f i c i a l D e p a r t m e n t o f t h e A r m y p o s i t i o n u n l e s s s o d e s i g n a t e dby o t h e r a u t h o r i z e d d o c u m e n t s .
![Page 7: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/7.jpg)
BIO-MED, I n c . i n i t i a t e d Phase I c l i n i c a l t e s t i n g o f a n t i m a l a r i a ldrugs f r o m F e b r u a r y 1 9 7 5 t h r o u g h t h e i n i t i a l c o n t r a c t y e a r .These d r u g s w e r e d e v e l o p e d b y t h e a n t i m a l a r i a l d r u g p r o g r a m o fthe U . S . A r m y M e d i c a l R e s e a r c h a n d D e v e l o p m e n t Command. T e s t i n gwas p e r f o L w e d a t t h e Wa s h i n g t o n H o s p i t a l C e n t e r i n Wa s h i n g t o n ,D.C. u n d e r C o n t r a c t DAMD 1 7 - 7 5 - C - 5 0 3 6 . A c h r o n i c s a f e t y a n dt o l e r a n c e s t u d y o f m e f l o q u i n e w a s s t a r t e d i n S e p t e m b e r 1 9 7 5 . T h es t u d y i n c l u d e s w e e k l y a d m i n i s t r a t i o n o f 5 0 0 mg o f d r u g o r p l a c e b ot o 5 0 h e a l t h y s u b j e c t s f o r a 5 2 - w e e k d u r a t i o n . N o a d v e r s er e a c t i o n s h a v e b e e n d e t e c t e d d u r i n g t h e i n i t i a l s t u d y m o n t h s a n dcomp l i ance i s e x c e l l e n t . I f t h e d r u g i s w e l l t o l e r a t e d t h r o u g h -o u t t h e s t u d y i n t e r v a l i t i s a n t i c i p a t e d t h a t , c l i n i c a l t r i a l s f o rm e f l o q u i n e u s e d a s a p r o p h y l a c t i c a g e n t may b e c o n s i d e r e d .
A n o t h e r q u i n o l i n e m e t h a n o l , WR 184,806-H3PO4 h a s b e e n a d m i n i s t e r e dto human s u b j e c t s i n s h o r t t e r m s a f e t y a n d t o l e r a n c e s t u d i e s .S i n g l e a n d m u l t i p l e o r a l d o s e s w e r e t e s t e d u s i n g d o u b l e - b l i n dr i s i n g d o s e l e v e l s . S i n g l e o r a l d o s e s w e r e w e l l t o l e r a t e d u p t othe 1 0 0 0 mg d o s e l e v e l : a l l 6 s u b j e c t s r e c e i v i n g 1200 t o 1 4 0 0 mgo f d r u g a s a s i n g l e o r a l d o s e h a d c o m b i n a t i o n s o f l i g h t - h e a d e d -ness w i t h a s s o c i a t e d d i f f i c u l t i e s s u c h a s c o n c e n t r a t i n g a n df o c u s i n g , h e a d a c h e , n a u s e a , i n s o m n i a , a n d u n u s u a l d r e a m s . T h esymptoms w e r e m i l d a n d o f l e s s t h a n 2 4 h o u r s d u r a t i o n i n a l l s u b -j e c t s . M u l t i p l e d o s e s t u d i e s c o n s i s t e d o f 9 d o s e s o f d r u g o rp l a c e b o a d m i n i s t e r e d e v e r y 8 h o u r s f o r a t o t a l o f 7 2 h o u r s . •I n t o l e r a n c e o c c u r r e d a t t h e 4 0 0 mg i n d i v i d u a l o r 3600 mg t o t a ldose l e v e l w i t h symptoms s i m i l a r t o t h o s e f o l l o w i n g s i n g l e d o s ea d m i n i s t r a t i o n . N o p h y s i c a l o r l a b o r a t o r y a b n o r m a l i t i e s w e r ea s s o c i a t e d w i t h t h e a d m i n i s t r a t i o n o f WR 184 ,806 .H3PO4.
S i n g l e o r a l d o s e s o f m e f l o q u i n e i n Phase I I s t u d i e s h a v e n o t b e e n •u n i v e r s a l l y e f f e c t i v e i n p a r a s i t e e r a d i c a t i o n . T h e s a f e t y a n dt o l e r a n c e o f r e p e a t i n g a " c u r a t i v e " s i n g l e d o s e 7 d a y s a f t e r t h e1 s t d o s e i s b e i n g t e s t e d . A d d i t i o n a l l y , a p r o t o c o l h a s b e e nd e s i g n e d , p r o c e s s e d , a n d a p p r o v e d f o r i m p l e m e n t a t i o n t o d e t e r m i n ethe t o p t o l e r a t e d s i n g l e o r a l d o s e o f m e f l o q u i n e . T h i s p r o t o c o ls h o u l d b e i m p l e m e n t e d e a r l y i n t h e n e x t c o n t r a c t y e a r .
E x t e n s i o n o f Phas,e I c l i n i c a l t e s t i n g o f m e f l o q u i n e i s w a r r a n t e dto p e r m i t f u r t h e r a p p l i c a t i o n i n Phase I I a n d Phase I I I t e s t i n g .WR 184,806•H3PO4 s t u d i e s d e m o n s t r a t e d t o l e r a n c e a t d o s e l e v e l sw h i c h may b e a d e q u a t e f o r c l i n i c a l p u r p o s e s . I n t o l e r a n c e i sm a n i f e s t e d b y t e m p o r a r y n o n - i n c a p a c i t a t i n g s y m p t o m a t o l o g y w i t h o u ta s s o c i a t e d p h y s i c a l o r l a b o r a t o r y a b n o r m a l i t i e s a t t r i b u t e d t o t h ed rug .
SUMMARY
![Page 8: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/8.jpg)
FOREWORD
Under t e r m s o f t h e c o n t r a c t , P h a s e I c l i n i c a l t e s t i n g o f a n t i -m a l a r i a l d r u g s w a s p e r f o r m e d a t t h e Wa s h i n g t o n H o s p i t a l C e n t e r .A l l p r o t o c o l s w e r e p r o c e s s e d b y t h e c o n t r a c t o r ' s O r g a n i z a t i o n a lReview a n d Human S u b j e c t (Human U s e ) c o m m i t t e e s p r i o r t o s u b m i s -s i o n t o t h e Wa s h i n g t o n H o s p i t a l C e n t e r R e s e a r c h C o m m i t t e e .
A l l p r o t o c o l s w e r e p r o c e s s e d a n d a p p r o v e d b y t h e Wa s h i n g t o nH o s p i t a l C e n t e r p r i o r t o i m p l e m e n t a t i o n . T h e Wa s h i n g t o nH o s p i t a l C e n t e r i s a p p r o v e d f o r p e r f o r m a n c e o f c l i n i c a l r e s e a r c hby t h e D e p a r t m e n t o f H e a l t h , E d u c a t i o n , a n d W e l f a r e . ( D H E WAssurance N o . G O 1 8 0 )
6
![Page 9: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/9.jpg)
TABLE OF CONTENTS
TITLE P A G E
T i t l e Page 1
Repor t D o c u m e n t a t i o n ( D D 1473 ) 2
Summary 5
Foreward 6
O b j e c t i v e s 8
Methods a n d R e s u l t s 8
Study Summary 1 0Exper imen t N o . 2 : W R 184,806.H3PO4Shor t Te r m Dosage, S a f e t y a n d To l e r a n c eR i s i n g S i n g l e Dose L e v e l s
15Study SummaryExper imen t No . 2 : W R 184,806-H3PO4Shor t Te r m Dosage, S a f e t y a n d To l e r a n c eM u l t i p l e Dose L e v e l s
Conc lus ions 1 9
D i s t r i b u t i o n L i s t 2 0
![Page 10: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/10.jpg)
OBJECTIVES
Genera l : T o i n i t i a t e P h a s e I C l i n i c a l Te s t i n g o f a n t i m a l a r i a ldrugs a t t h e Wa s h i n g t o n H o s p i t a l C e n t e r u s i n g m e t h o d o l o g yp r o v i d i n g maximum p r o t e c t i o n f o r t h e h e a l t h a n d w e l f a r e o fp a r t i c i p a t i n g s u b j e c t s .
S p e c i f i c :
1. T o e s t a b l i s h a s p r o j e c t a p p r o v i n g a n d m o n i t o r i n g c o m p o n e n t s ,BIO-MED O r g a n i z a t i o n a l R e v i e w a n d Human U s e C o m m i t t e e s . T h eWash ing ton H o s p i t a l C e n t e r p r o c e s s i n g a g e n c i e s f o r c l i n i c a lr e s e a r c h w i l l a l s o b e u s e d .
2. T o i n i t i a t e a c h r o n i c s a f e t y a n d t o l e r a n c e s t u d y o f m e f l o -q u i n e , a q u i n o l i n e m e t h a n o l w i t h d e m o n s t r a t e d e f f i c a c y f b r _p r e v e n t i o n a n d t h e r a p y o f m u l t i - d r u g r e s i s t a n t P.m a l a r i a . T h e s t u d y i n c l u d e s w e e k l y a d m i n i s t r a t i o n o f 5 0 0mg d r u g o r p l a c e b o f o r 5 2 weeks t o 5 0 s u b j e c t s .
3. T o p e r f o r m s h o r t t e r m s a f e t y a n d t o l e r a n c e t e s t i n g o fWR 184 ,806•H3PO4, a q u i n o l i n e m e t h a n o l w i t h some p h y s i c a land b i o l o g i c c h a r a c t e r i s t i c s o b s e r v e d i n p r e - c l i n i c a l t r i a l sw h i c h s u g g e s t p o t e n t i a l a d v a n t a g e s a s c o m p a r e d w i t h p r e v i -o u s l y t e s t e d q u i n o l i n e m e t h a n o l s .
4. T o d e t e r m i n e t h e t o p t o l e r a t e d s i n g l e o r a l d o s e o f m e f l o q u i n e .
5. T o d e t e r m i n e t h e s a f e t y a n d t o l e r a n c e o f r e p e a t i n g a d m i n i -s t r a t i o n o f a " c u r a t i v e " s i n g l e o r a l d o s e o f m e f l o q u i n e 7days a f t e r t h e f i r s t a d m i n i s t r a t i o n .
METHODS AND RESULTS
1 O r g a n i z a t i o n a l R e v i e w a n d Human U s e C o m m i t t e e s :BIO-MED e s t a b l i s h e d a n O r g a n i z a t i o n a l R e v i e w C o m m i t t e ei n c l u d i n g p h y s i c i a n s q u a l i f i e d i n r e s e a r c h a n d c l i n i c a lm e d i c i n e who a r e n o t o f f i c e r s o r e m p l o y e e s o f BIO-MED.Th i s e l i m i n a t e s a p o t e n t i a l e l e m e n t o f b i a s i n r e v i e w i n gp r o t o c o l s . T h e c o m m i t t e e e v a l u a t e s p r o t o c o l s f o r s c i e n t i f i cm e r i t a n d r i s k t o t h e s u b j e c t a s w e l l a s r e f i n i n g m e t h o d o l -ogy a s a p p r o p r i a t e .
F o l l o w i n g a p p r o v a l b y t h e O r g a n i z a t i o n a l R e v i e w C o m m i t t e ethe p r o t o c o l i s p r e s e n t e d t o t h e Human Use C o m m i t t e e w h i c hi s c o m p r i s e d o f l a y i n d i v i d u a l s w i t h a n i n t e r e s t i n c l i n i c a lr e s e a r c h a n d p r o t e c t i o n o f t h e human s u b j e c t s . M o s t membershave p a r t i c i p a t e d a s s t u d y s u b j e c t s a n d many a r e g r a d u a t es t u d e n t s i n l o c a l u n i v e r s i t i e s . T h i s c o m m i t t e e i s f r e es t a n d i n g , e l e c t s i t s o w n o f f i c e r s , a n d s e r v e s t h e v i t a lf u n c t i o n o f a n o n - m e d i c a l c o m m i t t e e i n a s s u r i n g t h e c i v i l
8
![Page 11: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/11.jpg)
r i g h t s o f t h e s u b j e c t s a r e p r o t e c t e d . I n a d d i t i o n t oa s s u r i n g m in imum d i s c o m f o r t a n d r i s k t o s u b j e c t s , t h ecommi t tee h a s o n o c c a s i o n recommended p r o t o c o l m o d i f i c a -t i o n s o f a s c i e n t i f i c n a t u r e w h i c h h a v e b e e n a d o p t e d .
A f t e r a p p r o v a l b y t h e Human U s e C o m m i t t e e , e a c h p r o t o c o li s s u b m i t t e d t o t h e R e s e a r c h C o m m i t t e e o f t h e Wa s h i n g t o nH o s p i t a l C e n t e r a n d i s p r o c e s s e d t h r o u g h t h e g o v e r n i n gb o d i e s . T h e Wa s h i n g t o n H o s p i t a l C e n t e r i s a p p r o v e d b yDHEW f o r p e r f o r m a n c e o f C l i n i c a l R e s e a r c h .
The p r o c e s s h a s r e s u l t e d i n e x t r a o r d i n a r y a t t e n t i o n t othe c o m f o r t a n d p r o t e c t i o n o f s u b j e c t s a s a Human U s eCommit tee member m o n i t o r s e a c h s t u d y " o n - s i t e " p r o v i d i n gs u g g e s t i o n s t o i m p r o v e c o m p l i a n c e a s w e l l a s s u b j e c tc o m f o r t .
O v e r a l l , t h e p r o j e c t p r o c e s s i n g p r o c e d u r e w i t h i t s m u l t i p l er e v i e w a n d a p p r o v a l c o m p o n e n t s h a s p r o v i d e d t h o r o u g hc o n s i d e r a t i o n a n d b e n e f i t v e r s u s r i s k f a c t o r s a n d h a s n o tbeen u n d u l y cumbersome.
2. M e f l o q u i n e - - 5 2 Week S t u d y :Th is d o u b l e - b l i n d s t u d y was d e s i g n e d t o p r o v i d e f i v e g r o u p so f 1 0 s u b j e c t s e a c h i n c l u d i n g d r u g a d m i n i s t e r e d a n d c o n t r o ls u b j e c t s . E a c h s u b j e c t w i l l r e c e i v e a s i n g l e 5 0 0 mg o r a ldose o f d r u g o r p l a c e b o w e e k l y f o r 5 2 w e e k s . T h e f i r s tgroup e n t e r e d s t u d y i n S e p t e m b e r 1 9 7 5 a n d a t t h i s t i m et h r e e g r o u p s ( 3 0 s u b j e c t s ) a r e i n s t u d y . T h e d u r a t i o n o fthe s t u d y r e q u i r e s c a r e f u l s e l e c t i o n o f s u b j e c t s s i n c em o t i v a t i o n m u s t p e r s i s t t o m a i n t a i n a n a c c e p t a b l y l o wd r o p o u t r a t e . C o m p r e h e n s i v e m e d i c a l e v a l u a t i o n i s p e r f o r m e ds e r i a l l y . N o c h a n g e s a t t r i b u t a b l e t o d r u g a d m i n i s t r a t i o nhave b e e n n o t e d i n a n y s u b j e c t .
3. S h o r t Te r m S a f e t y a n d To l e r a n c e , WR 1 8 4 , 8 0 6 . 11 ' 1130 4 :
The s t u d i e s w e r e i n i t i a t e d A p r i l 1 9 7 5 u s i n g a s i n g l e o r a ldose, d o u b l e - b l i n d , r i s i n g d o s e l e v e l m e t h o d . T h e d r u g wasw e l l t o l e r a t e d u p t o t h e 1 0 0 0 mg d o s e l e v e l : a l l s i x s u b -j e c t s r e c e i v i n g 1 2 0 0 t o 1 4 0 0 m g d r u g m a n i f e s t e d c o m b i n a t i o n so f l i g h t - h e a d e d n e s s w i t h a s s o c i a t e d d i f f i c u l t i e s c o n c e n t r a -t i n g a n d f o c u s i n g , h e a d a c h e , n a u s e a , i n s o m n i a , a n d u n u s u a ldreams. T h e symptoms w e r e m i l d a n d o f l e s s t h a n 2 4 h o u r sd u r a t i o n . N o o t h e r c h a n g e s a t t r i b u t e d t o d r u g w e r e o b s e r v e d .The c o m p l e t e r e p o r t f o r s u b m i s s i o n t o t h e t e c h n i c a l m o n i t o ri s i n p r e p a r a t i o n . T h e S t u d y Summary i s p r e s e n t e d i n t h ef o l l o w i n g p a g e s :
9
![Page 12: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/12.jpg)
•
BlO- MED, Inc°
INTRODUCTION:
EXPERIMENT NO. 2 : W R 184,806-H3PO4SHORT TERM DOSAGE SAFETY AND TOLERANCE
RISING SINGLE DOSE LEVELS
STUDY SUMMARY
Tel: (202) 882-0977
The s t u d y was p e r f o r m e d t o d e t e r m i n e t h e s h o r t t e L m dosages a f e t y a n d t o l e r a n c e o f WR 184,806-H3PO4 a d m i n i s t e r e d o r a l l yto human s u b j e c t s . A t o t a l o f 1 2 s t u d y i n t e r v a l s w e r e u s e dto a d m i n i s t e r d r u g o r p l a c e b o t o 4 5 s u b j e c t s .
SUBJECTS:
R e c r u i t m e n t :
S u b j e c t s w e r e h e a l t h y m a l e s a g e d 2 1 t o 4 5 y e a r s w e i g h i n g b e -tween 5 0 - 1 0 0 k g . T h e y w e r e r e c r u i t e d f r o m t h e Wa s h i n g t o n ,D.C. m e t r o p o l i t a n a r e a a n d w e r e h i r e d a s t e m p o r a r y emp loyees .
Sc reen ing :
Cand idates f o r emp loymen t u n d e r w e n t q u a l i f y i n g e x a m i n a t i o n sto o b t a i n t h e s u b j e c t s f o r s t u d y . T h e i n i t i a l e v a l u a t i o ni n c l u d e d a c o m p l e t e h i s t o r y a n d p h y s i c a l e x a m i n a t i o n , c h e s tx - r a y , e l e c t r o c a r d i o g r a m a n d t h e f o l l o w i n g t e s t s : u r i n a l y s i s ,w h i t e b l o o d c e l l a n d d i f f e r e n t i a l c o u n t , r e d b l o o d c e l l c o u n t ,hemog lob in , h e m a t o c r i t , MCV, NCR, MCHC, p l a t e l e t c o u n t , g l u c o s e ,BUN, c r e a t i n i n e , N a-F, C l-, C O 2 , u r ic a c id , t o ta l p r ot e in ,
a lbumin , g l o b u l i n , c a l c i u m , p h o s p h a t e , c h o l e s t e r o l , t r i g l y c e r -i d e s , a l k a l i n e p h o s p h a t a s e , SGOT, SGPT, L D H , t o t a l b i l i r u b i n .L a b o r a t o r y t e s t s w e r e p e r f o r m e d i n d u p l i c a t e b y N a t i o n a l H e a l t hL a b o r a t o r i e s , I n c . u s i n g s t a n d a r d methods . C h e s t x - r a y s w e r epe r f o rmed i n t h e D e p a r t m e n t o f R a d i o l o g y a t t h e Wa s h i n g t o nH o s p i t a l C e n t e r . E l e c t r o c a r d i o g r a m s w e r e p e r f o r m e d b y t r a i n e dp e r s o n n e l u s i n g a Cambr idge V S - 4 p o r t a b l e e l e c t r o c a r d i o g r a p hmachine. U r i n a l y s e s w e r e p e r f o r m e d b y p h y s i c i a n i n v e s t i g a t o r si n t h e r e s e a r c h u n i t l a b o r a t o r y u s i n g s t a n d a r d me thods .
I n f o rmed C o n s e n t :
Q u a l i f i e d c a n d i d a t e s w e r e p r e s e n t e d w i t h a c o m p l e t e e x p l a n a t i o no f t h e b a c k g r o u n d a n d r a t i o n a l f o r t h e s t u d y a s w e l l a s p r o c e -dures t o b e u s e d . C a n d i d a t e s w e r e i n t e r v i e w e d a s a g r o u p a n di n d i v i d u a l l y . A t i n d i v i d u a l i n t e r v i e w s i t was a s c e r t a i n e d t h ec a n d i d a t e u n d e r s t o o d t h e s t u d y a n d p e r s o n a l r i s k f a c t o r s .Q u a l i f i e d c a n d i d a t e s w e r e a s k e d t o r e a d a n d p e r m i t t e d t o s i g nthe c o n s e n t s t a t e m e n t .
10
Washington, D.C. 20010
![Page 13: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/13.jpg)
Exp. 2 : S t u d y Summary ( C o n t . )R i s i n g S i n g l e Dose L e v e l s
Human Use C o m m i t t e e :
Th is f r e e s t a n d i n g c o m m i t t e e composed o f c o m m u n i t y members a n do f s i m i l a r a g e a n d o c c u p a t i o n t o t h e human s u b j e c t g r o u p m u s tg i ve a p p r o v a l f o r e a c h s t u d y p r i o r t o i m p l e m e n t a t i o n . A mem-be r o f t h e human u s e c o m m i t t e e p a r t i c i p a t e d i n t h e c o n s e n ti n t e r v i e w s a n d made f r e q u e n t v i s i t s t o t h e r e s e a r c h u n i t t om o n i t o r t h e s t u d y a n d a s s u r e t h e s u b j e c t s ' h e a l t h a n d w e l f a r ewere g i v e n p r i m a r y c o n s i d e r a t i o n . E a c h s u b j e c t c l e a r l y u n d e r -s tood t h a t h e c o u l d t e r m i n a t e h i s p a r t i c i p a t i o n i n t h e s t u d ya t a n y t i m e .
HOUSING:
Sub jec t s w e r e h o u s e d o n t h e c l i n i c a l r e s e a r c h u n i t o f t h eWash ing ton H o s p i t a l C e n t e r , u t i l i z i n g s e m i - p r i v a t e rooms w i t hmodern f a c i l i t i e s . A l o u n g e a r e a was a v a i l a b l e w h i c h c o n t a i n e dt e l e v i s i o n , r e a d i n g m a t e r i a l s , games , c h a i r s , a n d d e s k s . S u b -j e c t s , s u p e r v i s e d b y t h e i n v e s t i g a t i n g t e a m , w e r e a l l o w e d t ouse t h e t e n n i s c o u r t s , s w i m m i n g p o o l a n d r e c r e a t i o n a l f a c i l i t i e so f t h e Wa s h i n g t o n H o s p i t a l C e n t e r . A c h o i c e o f m e a l s was madea v a i l a b l e t o e a c h o f t h e s u b j e c t s b y t h e F o o d S e r v i c e D e p a r t m e n ta t t h e Wa s h i n g t o n H o s p i t a l C e n t e r . E a c h s u b j e c t u n d e r w e n ts e r i a l p h y s i c a l e x a m i n a t i o n s i n t h e u n i t e x a m i n i n g r o o m a n ds p e c i a l t e s t s w e r e p e r f o r m e d i n s p e c i a l t y a r e a s w i t h i n t h eh o s p i t a l .
METHODS:
Drug a d m i n i s t r a t i o n :Drug l o t s u s e d , d o s i n g s c h e d u l e s , n u m b e r o f s u b j e c t s i n e a c hs tudy p e r i o d a n d i n c r e m e n t a l i n c r e a s e s i n d o s e s a r e o n f i l e .16 s u b j e c t s r e c e i v e d d r u g a n d 1 3 p l a c e b o .C l i n i c a l a n d l a b o r a t o r y e v a l u a t i o n s :S e r i a l c o m p r e h e n s i v e m e d i c a l e v a l u a t i o n i n c l u d i n g p h y s i c a l , b i o -chemica l , h e m a t o l o g i c a n d p h o t o t o x i c i t y t e s t i n g was p e r f o r m e d o na l l s u b j e c t s . S p e c i a l t e s t s w e r e p e r f o r m e d i n s e l e c t e d g r o u p sa t 1000 t o 1 4 0 0 mgm d o s e l e v e l s a s f o l l o w s : o r t h o s t a t i c t o l e r -ance, a u d i o m e t r y a n d e l e c t r o n y s t a g m o g r a p h y. A t t h e 1400 mgm dosed e t a i l e d o p h t h a l m o l o g i c e x a m i n a t i o n s w e r e p e r f o r m e d b e f o r e a n da f t e r d o s i n g .
RESULTS:
Symptoms a n d p h y s i c a l f i n d i n g s :The o n s e t , d u r a t i o n a n d d e s c r i p t i o n o f symptoms a n d p h y s i c a lf i n d i n g s o n a l l s u b j e c t s a r e o n f i l e . N o symptoms o r f i n d i n g ss u g g e s t i v e o f i n t o l e r a n c e t o WR 184,806-H3PO4 w e r e o b s e r v e d b e -low t h e 1000 mgm d o s e . T w o o f t h e 4 s u b j e c t s r e c e i v i n g 1000 mgmhad t r a n s i e n t symptoms s u b s e q u e n t l y a t t r i b u t e d t o d o s i n g : o n ewas l i g h t h e a d e d f o r o n e m i n u t e a n d t h e o t h e r c o m p l a i n e d o ftempora ry m i l d l i g h t h e a d e d n e s s a n d nausea . T h e f o u r s u b j e c t sr e c e i v i n g 1 2 0 0 mgm a n d t h e t w o r e c e i v i n g 1400 mgm a l l h a d symptom
11
![Page 14: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/14.jpg)
Exp. 2 : S t u d y Summary ( C o n t . )R i s i n g S i n g l e Dose L e v e l s
p a t t e r n s s u g g e s t i v e o f i n t o l e r a n c e i n c l u d i n g c o m b i n a t i o n s o fl i g h t h e a d e d n e s s w i t h a s s o c i a t e d d i f f i c u l t i e s c o n c e n t r a t i n gand f o c u s i n g , h e a d a c h e , n a u s e a , i n s o m n i a a n d u n u s u a l d r e a m s .I n a l l s u b j e c t s t h e symptoms w e r e m i l d a n d o f l e s s t h a n t w e n t y -f o u r h o u r s d u r a t i o n .
P h y s i c a l e x a m i n a t i o n s :Two a b n o r m a l i t i e s w e r e n o t e d i n i t i a l l y a f t e r d o s i n g . O n es u b j e c t h a d a p o i s o n o a k r a s h w h i c h was n o t c o n s i d e r e d d r u gr e l a t e d . T h e o t h e r s u b j e c t h a d a t e m p o r a r y d e c r e a s e i na m p l i t u d e o f accommodat ion w h i c h was p o s s i b l y b u t n o t p r o b a b l ydrug r e l a t e d .
L a b o r a t o r y t e s t s :There w e r e n o s i g n i f i c a n t a l t e r a t i o n s i n t h e s e t e s t s a t t r i b u t e dto d r u g i n g e s t i o n .U r i n a l y s e s - T h e r e w e r e n o s i g n i f i c a n t a l t e r a t i o n s i n u r i n ep r o t e i n o r changes i n u r i n a r y s e d i m e n t a t t r i b u t e d t o d r u gi n g e s t i o n .E l e c t r o c a r d i o g r a p h y a n d p h o t o t o x i c i t y t e s t i n g - N o e l e c t r o -c a r d i o g r a p h i c changes a t t r i b u t a b l e t o d r u g i n g e s t i o n w e r eobserved . P h o t o t o x i c i t y was n o t p r o d u c e d u n d e r c o n d i t i o n so f t h e s t u d y .
S p e c i a l t e s t s :O r t h o s t a t i c To l e r a n c e :
Tes ts f o r o r t h o s t a t i c t o l e r a n c e w e r e p e r f o r m e d o n 1 0 s u b j e c t s .Only o n e s u b j e c t d e m o n s t r a t e d o r t h o s t a t i c i n t o l e r a n c e f o l l o w -i n g o r a l a d m i n i s t r a t i o n o f 1000 mgm o f t h e d r u g . T h i s s u b j e c td i d n o t h a v e symptoms. I t was c o n c l u d e d t h a t n o n - r o t a t i o n a lv e r t i g o f o l l o w i n g a d m i n i s t r a t i o n o f WR 184,806.H3PO4 i n t h i ss t u d y was n o t a s s o c i a t e d w i t h o r t h o s t a t i c i n t o l e r a n c e .
Aud iomet ry a n d E l e c t r o n y s t a g m o g r a p h y ( E N G ) :One s u b j e c t who i n g e s t e d 1000 mgm o f t h e d r u g h a d a m i l d u n i -l a t e r a l s e n s o r i n e u r a l h e a r i n g l o s s . A l l o t h e r s u b j e c t s h a dnormal a u d i o g r a m s .ENG a n a l y s i s r e v e a l e d a n o r m a l l y f u n c t i o n i n g v e s t i b u l a r mecha-n ism f o r e a c h s u b j e c t w i t h t h e f o l l o w i n g t h r e e e x c e p t i o n s : S u b -j e c t No . 3 9 r e v e a l e d a p o s i t i o n a l nys tagmus p r o b a b l y r e l a t e d t ov e s t i b u l o g e n i c d r u g e x p o s u r e i m m e d i a t e l y p r i o r t o s t u d y ; r e p e a tENG 4 weeks l a t e r was n o r m a l . S u b j e c t N o . 3 3 h a d a 2 2 p e r c e n tdecrease i n l e f t v e s t i b u l a r r e s p o n s e s u g g e s t i v e o f p e r i p h e r a lp a t h o l o g y. E N G was n o r m a l when r e p e a t e d . T h e d e c r e a s e d v e s -t i b u l a r r e s p o n s e was n o t c o n s i d e r e d d r u g r e l a t e d s i n c e i t wasu n i l a t e r a l . F i n a l l y , s u b j e c t number 101id v o m i t e d f o l l o w i n gc o l d w a t e r i r r i g a t i o n ; h i s ENG was n o r m a l . T h e r e was n o e v i -dence u n d e r c o n d i t i o n s o f t h e s t u d y t h a t WR 184,806-H3PO4a f f e c t e d t h e v e s t i b u l a r mechanism.
12
![Page 15: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/15.jpg)
Exp. 2 : S t u d y Summary ( C o n t . )R i s i n g S i n g l e Dose L e v e l s
O p h t h a l m o l o g i c e v a l u a t i o n :
Tes t s w e r e p e r f o r m e d o n s u b j e c t s r e c e i v i n g 1 4 0 0 mgm o f WR184,806.H3PO4. S u b j e c t Number 10Ba c o m p l a i n e d o f b l u r r e dv i s i o n when r e a d i n g . T h e o n l y a b n o r m a l i t y was a d e c r e a s ei n t h e a m p l i t u d e o f accommodat ion . T h i s p e r s i s t e d f o r t w odays a n d r e t u r n e d t o n o r m a l w i t h i n a week . T h e p r e s e n c e o fa s m a l l r e f r a c t i v e a s t i g m a t i s m t e n d e d t o e x a g g e r a t e h i ssymptomato logy. T h e t e m p o r a r y change i n accommodat i ve r e -serve was p o s s i b l y d r u g r e l a t e d .
CONCLUSION:
I t was c o n c l u d e d t h a t i n t o l e r a n c e t o s i n g l e d o s e a d m i n i s t r a t i o no f WR 184,806.H3PO4 was m a n i f e s t e d b y l i g h t h e a d e d n e s s a n da s s o c i a t e d symptoms w i t h o u t d e t e c t e d o b j e c t i v e c h a n g e . I n -t o l e r a n c e was m a r g i n a l a t t h e 1000 mgm a n d d e f i n i t e a t t h e1200 mgm d o s e l e v e l . S y m p t o m a t o l o g y was m i l d t o m o d e r a t e ,most n o t i c e a b l e a t 1400 mgm, a n d o f l e s s t h a n t w e n t y - f o u rhours d u r a t i o n i n a l l s u b j e c t s .
13
![Page 16: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/16.jpg)
3. S h o r t Te r m S a f e t y a n d To l e r a n c e , WR 184,806-H3PO4: ( C o n t . )
F o l l o w i n g c o m p l e t i o n o f t h e s i n g l e o r a l d o s e s t u d y , am u l t i p l e o r a l d o s e s t u d y was i n i t i a t e d . A d o u b l e - b l i n d ,r i s i n g d o s e l e v e l was u s e d w i t h d r u g o r p l a c e b o a d m i n i s -t e r e d e v e r y e i g h t h o u r s f o r n i n e d o s e s . S y m p t o m s o fl i g h t - h e a d e d n e s s a n d t r e m u l o u s n e s s , m i l d a n d t e m p o r a r yo c c u r r e d a f t e r t h e s i x t h a d m i n i s t r a t i o n o f t h e 4 0 0 mgdose o f d r u g i n b o t h s u b j e c t s r e c e i v i n g a t o t a l d o s e o f3600 mg. T h e s t u d y was c o m p l e t e d O c t o b e r 1 9 7 5 . T h eStudy Summary i s p r e s e n t e d i n t h e f o l l o w i n g p a g e s :
14
![Page 17: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/17.jpg)
— m S U B J E C T S :
— M E D9 —r i c o
INTRODUCTION:
EXPERIMENT NO. 2 : W R 184,806.H3PO4SHORT TERM DOSAGE SAFETY AND TOLERANCE
MULTIPLE DOSE LEVELS
STUDY SUMMARY
Tel: (202) 8 8 2-0 9 7 7
I n s i n g l e d o s e s t u d i e s p r e v i o u s l y r e p o r t e d , n o i n t o l e r a n c e•to WR 184,806.H3PO4 was o b s e r v e d b e l o w t h e 1 0 0 0 mg d o s el e v e l . A t h i g h e r d o s e l e v e l s , l i g h t h e a d e d n e s s w i t h a s s o c i -a ted d i f f i c u l t i e s c o n c e n t r a t i n g a n d f o c u s i n g , h e a d a c h e ,nausea a n d s l e e p d i s t u r b a n c e s o c c u r r e d . T h e r e w e r e n oa s s o c i a t e d o b j e c t i v e f i n d i n g s a n d t h e symptoms w e r e o f l e s sthan t w e n t y - f o u r h o u r s d u r a t i o n . T h i s s t u d y was p e r f o r m e d
2 t o d e t e r m i n e t h e s h o r t t e r m s a f e t y a n d t o l e r a n c e o f WRm m 1 8 4 , 8 0 6 . H 3 P O 4 a d m i n i s t e r e d o r a l l y i n m u l t i p l e d o s e s . Ac— — t o t a l o f e i g h t s t u d y l e v e l s w e r e u s e d t o a d m i n i s t e r d r u g o rN
p lacebo t o 2 9 s u b j e c t s .0 2?..-
• ' .- T h e s u b j e c t s w e r e r e c r u i t e d f r o m t h e Wa s h i n g t o n , D . C .m e t r o p o l i t a n a r e a a n d w e r e h i r e d a s t e m p o r a r y emp loyees .=
ig A d v e r t i s e m e n t s i n u n i v e r s i t y newspapers p r o v i d e d i n i t i a l' f Em c o n t a c t s w i t h p o t e n t i a l s u b j e c t s . T h i s m e t h o d p l u s p o s i t i v e
:-I5 0 recommendations by participating subjects to their class-
5m m a t e s e n l a r g e d t h e c a n d i d a t e p o o l . A p p r o x i m a t e l y 807 o f t h e_c0 • s u b j e c t s w e r e u n i v e r s i t y s t u d e n t s w i t h s u p e r i o r m o t i v a t i o n ,m u n d e r s t a n d i n g a n d c o m p l i a n c e .oom S c r e e n i n g :c •;:--m 0E —›.. - C a n d i d a t e s f o r emp loymen t u n d e r w e n t q u a l i f y i n g e x a m i n a t i o n sm >m t o o b t a i n t h e s u b j e c t s f o r s t u d y . T h e i n i t i a l e v a l u a t i o no _1m i n c l u d e d a c o m p l e t e h i s t o r y a n d p h y s i c a l e x a m i n a t i o n , c h e s t, m0 m x - r a y , e l e c t r o c a r d i o g r a m a n d t h e f o l l o w i n g t e s t s : u r i n a l y s i s ,o c. ,J0 — w h i t e b l o o d c e l l a n d d i f f e r e n t i a l c o u n t , r e d b l o o d c e l l c o u n t ,
hemog lob in , h e m a t o c r i t , MCV, MCH, MCHC, p l a t e l e t c o u n t , g l u -.5- ..
cose, BUN, c r e a t i n i n e , N a + , K + , C l-, C O 2 , u r i c a c i d , t o t a l
= .-Es E protein, albumin, globulin, calcium, phosphate, cholesterol,
t r i g l y c e r i d e s , a l k a l i n e p h o s p h a t a s e , SGOT, SGPT, L D H , t o t a lm - 0
.c < b i l i r u b i n a n d G6PD. L a b o r a t o r y t e s t s w e r e p e r f o r m e d i n d u p -l i c a t e b y N a t i o n a l H e a l t h L a b o r a t o r i e s , I n c . u s i n g s t a n d a r d
"o =o m. — m e t h o d s . C h e s t x - r a y s w e r e p e r f o r m e d i n t h e D e p a r t m e n t o fm R a d i o l o g y a t t h e Wa s h i n g t o n H o s p i t a l C e n t e r . E l e c t r o c a r d i o -
grams w e r e p e r f o r m e d b y t r a i n e d p e r s o n n e l u s i n g a Cambr idge
15
Washington, D.C. 20010
![Page 18: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/18.jpg)
Exp. 2 : S t u d y Summary ( C o n t . )M u l t i p l e Dose L e v e l s
VS-4 p o r t a b l e e l e c t r o c a r d i o g r a p h i c m a c h i n e . U r i n a l y s e swere p e r f o / m e d b y p h y s i c i a n i n v e s t i g a t o r s i n t h e r e s e a r c hu n i t l a b o r a t o r y u s i n g s t a n d a r d me thods .
I n f o rmed C o n s e n t :
Q u a l i f i e d c a n d i d a t e s w e r e p r e s e n t e d w i t h a c o m p l e t e e x p l a n a -t i o n o f t h e b a c k g r o u n d a n d r a t i o n a l e f o r t h e s t u d y a s w e l las p r o c e d u r e s t o b e u s e d . C a n d i d a t e s w e r e i n t e r v i e w e d i n agroup a n d i n d i v i d u a l l y . A t i n d i v i d u a l i n t e r v i e w s i t was a s -c e r t a i n e d t h a t t h e c a n d i d a t e u n d e r s t o o d t h e s t u d y a n d p e r s o n a lr i s k f a c t o r s . Q u a l i f i e d c a n d i d a t e s w e r e a s k e d t o r e a d a n dp e r m i t t e d t o s i g n t h e c o n s e n t s t a t e m e n t .
Human Use C o m m i t t e e :
Th is f r e e s t a n d i n g c o m m i t t e e composed o f commun i t y membersand o f s i m i l a r a g e a n d o c c u p a t i o n t o t h e human s u b j e c t g r o u pmust g i v e a p p r o v a l f o r e a c h s t u d y p r i o r t o i m p l e m e n t a t i o n .A member o f t h e Human Use C o m m i t t e e p a r t i c i p a t e d i n t h e c o n -sen t i n t e r v i e w s a n d made f r e q u e n t v i s i t s t o t h e r e s e a r c h u n i tt o m o n i t o r t h e s t u d y a n d a s s u r e t h e s u b j e c t s ' h e a l t h a n dw e l f a r e w e r e g i v e n p r i m a r y c o n s i d e r a t i o n . E a c h s u b j e c tc l e a r l y u n d e r s t o o d t h a t h e c o u l d t e r m i n a t e h i s p a r t i c i p a t i o ni n t h e s t u d y a t a n y t i m e .
HOUSING:
S u b j e c t s w e r e h o u s e d o n t h e C l i n i c a l R e s e a r c h U n i t o f t h eWash ing ton H o s p i t a l C e n t e r , u t i l i z i n g s e m i - p r i v a t e roomsw i t h modern f a c i l i t i e s . A l o u n g e a r e a was a v a i l a b l e w h i c hc o n t a i n e d t e l e v i s i o n , r e a d i n g m a t e r i a l s , g a m e s , c h a i r s a n ddesks. S u b j e c t s , s u p e r v i s e d b y t h e i n v e s t i g a t i n g t e a m , w e r ea l l o w e d t o u s e t h e t e n n i s c o u r t s , s w i m m i n g p o o l a n d r e c r e a -t i o n a l f a c i l t i t e s a t t h e Wa s h i g n t o n H o s p i t a l C e n t e r . A c h o i c eo f mea l s was made a v a i l a b l e t o e a c h o f t h e s u b j e c t s b y t h eFood S e r v i c e D e p a r t m e n t a t t h e Wa s h i n g t o n H o s p i t a l C e n t e r .Each s u b j e c t u n d e r w e n t s e r i a l p h y s i c a l e x a m i n a t i o n s i n t h eu n i t e x a m i n g r o o m a n d s p e c i a l t y a r e a s w i t h i n t h e h o s p i t a l .
METHODS:
The d o s i n g s c h e d u l e a n d number o f s u b j e c t s i n e a c h s t u d y p e r i o dare o n f i l e . S i x t e e n s u b j e c t s r e c e i v e d d r u g a n d 1 3 p l a c e b o .
C l i n i c a l a n d l a b o r a t o r y e v a l u a t i o n s :
S e r i a l c o m p r e h e n s i v e m e d i c a l e v a l u a t i o n i n c l u d i n g p h y s i c a l , b i o -chem ica l , h e m a t o l o g i c a n d p h o t o t o x i c i t y t e s t i n g was p e r f o r m e don a l l s u b j e c t s .
16
![Page 19: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/19.jpg)
Exp. 2 : S t u d y Summary ( C o n t . )M u l t i p l e Dose L e v e l s
RESULTS:
Symptoms a n d p h y s i c a l f i n d i n g s :
The o n s e t , d u r a t i o n a n d d e s c r i p t i o n o f symptoms a n d p h y s i c a lf i n d i n g s o n a l l s u b j e c t s a r e o n f i l e . M i l d symptoms o f t r a n -s i e n t d i a r r h e a , c o n s t i p a t i o n , l e t h a r g y , f l u s h i n g a n d d i s t u r b -i n g d reams o c c u r r e d i n b o t h c o n t r o l a n d s u b j e c t s r e c e i v i n gdrug. T w o s u b j e c t s , r e c e i v i n g 3600 mg d r u g ( 1 2 0 0 mg d a i l yf o r 3 d a y s ) c o m p l a i n e d o f v a g u e t r e m u l o u s n e s s a n d l i g h t h e a d e d -ness s i m i l a r t o t h a t o b s e r v e d when 1 2 0 0 - 1 4 0 0 mgs o f WR184,806.H3PO4 w e r e a d m i n i s t e r e d a s a s i n g l e d o s e i n a p r e v i o u ss t u d y. T w o o t h e r s u b j e c t s r e c e i v i n g 6 0 0 a n d 7 5 0 mg o f d r u gd a i l y e x p e r i e n c e d s l e e p d i s t u r b a n c e s . I n a l l s u b j e c t s t h eabove n o t e d symptoms w e r e m i l d , t e m p o r a r y a n d w i t h o u t a s s o c i -a ted p h y s i c a l o r l a b o r a t o r y a b n o r m a l i t i e s .
P h y s i c a l E x a m i n a t i o n :
One s u b j e c t r e c e i v i n g 3000 mg d r u g d e v e l o p e d a m a c u l o p a p u l a rrash 1 0 d a y s a f t e r c o m p l e t i o n o f d r u g a d m i n i s t r a t i o n w h i c hwas a l s o a s s o c i a t e d w i t h t h e s u b j e c t ' s u s e o f a c o m m e r c i a lsoap f o r t h e f i r s t t i m e . T h e r a s h d i s a p p e a r e d upon d i s c o n t i n -u a t i o n o f u s e o f t h e s o a p a n d was c o n s i d e r e d a s o a p p r e c i p i t a t e dc o n t a c t d e r m a t i t i s b y t h e c o n s u l t i n g d e r m a t o l o g i s t .M i l d s u n b u r n i n 2 s u b j e c t s a n d swimming p o o l c h e m i c a l c o n -j u n c t i v i t i s i n o n e s u b j e c t w e r e n o t c o n s i d e r e d d r u g r e l a t e d .
L a b o r a t o r y t e s t s :
E i g h t y - t h r e e p e r c e n t o f t h e s u b j e c t s h a d a t l e a s t o n e hema-t o l o g i c o r b i o c h e m i c a l a b n o r m a l i t y . A b n o r m a l i t i e s w e r e d i s -t r i b u t e d w i t h e q u a l f r e q u e n c y amongs t s u b j e c t s a d m i n i s t e r e ddrug a n d p l a c e b o . N o d e v i a t i o n s w e r e a s c r i b e d t o d r u gi n g e s t i o n .Ten s u b j e c t s h a d a b n o r m a l u r i n a l y s e s , 6 o f t h e s e r e c e i v e d d r u g .G l y c o s u r i a ( 1 + ) w i t h a n o r m a l b l o o d s u g a r was d e t e c t e d o ndays 2 a n d 4 i n o n e s u b j e c t r e c e i v i n g 9 0 0 mg o f d r u g . I n t e r -m i t t e n t t r a c e p r o t e i n u r i a was d e t e c t e d i n o n e s u b j e c t r e c e i v i n gdrug a s w e l l a s o n e who r e c e i v e d p l a c e b o . I n c r e a s e d numberso f r e d a n d w h i t e c e l l s i n t h e u r i n a r y s e d i m e n t i n c o n t r o l a n ddrug a d m i n i s t e r e d s u b j e c t s d e m o n s t r a t e d n o p a t t e r n a n d a r e n o tc o n s i d e r e d s t u d y r e l a t e d . N o s u b j e c t h a d c y l i n d r u r i a . N oe l e c t r o c a r d i o g r a p h i c changes a t t r i b u t a b l e t o d r u g i n g e s t i o nwere o b s e r v e d . P h o t o t o x i c i t y was n o t p r o d u c e d u n d e r c o n d i t i o n so f t h i s s t u d y .
17
![Page 20: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/20.jpg)
Exp. 2 : S t u d y Summary ( C o n t . )M u l t i p l e Dose L e v e l s
CONCLUSION:
P o s s i b l e i n t o l e r a n c e t o m u l t i p l e doses o f WR 184,806.H3PO4was d e t e c t e d . S o m e s u b j e c t s r e c e i v i n g d r u g , a s w e l l a sc o n t r o l s , e x p e r i e n c e d f l u s h i n g , v i v i d dreams a n d o t h e r symp-toms c o n s i d e r e d p o t e n t i a l l y d r u g r e l a t e d i n t h e p r e v i o u ss i n g l e d o s e s t u d y . T r e m u l o u s n e s s a n d l i g h t h e a d e d n e s so c c u r r e d o n t h e l a s t d a y o f d o s i n g i n t w o s u b j e c t s r e c e i v -i n g 3 6 0 0 mg t o t a l d o s e . T h e l a t e o n s e t o f t h e s e symptomsand s i m i l a r i t y t o symptoms o f i n t o l e r a n c e a t 1200 a n d 1400mg s i n g l e d o s e l e v e l s s u g g e s t s t h e y may b e d r u g r e l a t e d .G a s t r o i n t e s t i n a l symptoms o c c u r r e d i n t h e c o n t r o l s u b j e c t sas w e l l a s t h o s e r e c e i v i n g d r u g . I n t h e l a t t e r , t h e symptomsd i d n o t p e r s i s t o r i n c r e a s e i n s e v e r i t y w i t h c o n t i n u e d d r u ga d m i n i s t r a t i o n . N o p h y s i c a l o r l a b o r a t o r y a b n o r m a l i t i e swere a s c r i b e d t o d r u g i n g e s t i o n .
18
![Page 21: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/21.jpg)
4. T o p To l e r a t e d S i n g l e O r a l D o s e M e f l o q u i n e :Th is p r o t o c o l h a s b e e n p r o c e s s e d a n d a p p r o v e d f o r i m p l e -m e n t a t i o n . S c h e d u l e d t o i n i t i a t e s t u d y F e b r u a r y 1 9 7 6 .
5. M e f l o q u i n e :S a f e t y a n d t o l e r a n c e s i n g l e o r a l d o s e r e p e a t e d 7 d a y s a f t e rf i r s t a d m i n i s t r a t i o n . T h i s d o u b l e - b l i n d e d , r i s i n g d o s el e v e l s t u d y was i n i t i a t e d December 9 , 1 9 7 5 . A n y r e p o r t a tt h i s t i m e w o u l d b e p r e m a t u r e .
CONCLUSIONS:
The a c c o m p l i s h m e n t s o f t h e f i r s t c o n t r a c t y e a r may b e e n u m e r a t e das f o l l o w s :
1. T h e O r g a n i z a t i o n a l R e v i e w C o m m i t t e e a n d t h e Human U s e Commi t -tee a r e p e r f o r m i n g i n a s u p e r i o r m a n n e r. T h e Human UseCommittee members , b y p r o v i d i n g c o n t i n u o u s m o n i t o r i n g d u r i n gs t u d i e s , h a s p e r f o r m e d a s i g n i f i c a n t s e r v i c e i n t h e a r e a s o fs u b j e c t p r o t e c t i o n , u n d e r s t a n d i n g , a n d c o m p l i a n c e . T h eWash ing ton H o s p i t a l C e n t e r p a r t i c i p a t i o n h a s b e e n p r o d u c t i v eand n o t o b s t r u c t i v e . T h e c l o s e l i a i s o n w i t h t h e W a l t e r Reeds c i e n t i s t s i n c r e a s e s e f f i c i e n c y a n d p r o d u c t i v i t y .
2. T h e 5 2 - w e e k m e f l o q u i n e s t u d y i s w e l l u n d e r w a y. T h e c a r e f u ls e l e c t i o n o f s u b j e c t s a n d s u b j e c t management d u r i n g t h es t u d y s h o u l d a s s u r e a l o w d r o p o u t r a t e .
3. W R 1 8 4 , 8 0 6 . H 3PO4 i s a p r o m i s i n g compound b o t h b e c a u s e o f a na c c e p t a b l e t o p t o l e r a t e d d o s e a n d i n t o l e r a n c e m a n i f e s t e d b yt e m p o r a r y, n o n - i n c a p a c i t a t i n g symptoms w i t h o u t a s s o c i a t e dc l i n i c a l a b n o L m a l i t i e s .
4. T h e a p p l i c a t i o n o f m e f l o q u i n e i n Phase I I c l i n i c a l t r i a l st h r e a t e n e d t o o u t s t r i p n e e d e d Phase I t e s t i n g . T h i s t h r e a ti s b e i n g e l i m i n a t e d b y t h e P h a s e I t e s t i n g b e i n g p e r f o r m e dt h r o u g h t h i s c o n t r a c t .
19
![Page 22: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/22.jpg)
4 c o p i e s
12 c o p i e s
1 c o p y
1 c o p y
DISTRIBUTION L I S T
HODA (SORD-RP)WASH DC 2 0 3 1 4
Defense D o c u m e n t a t i o n C e n t e r (DDC)ATTN: D D C - T C ACameron S t a t i o n.A l e x a n d r i a , V i r g i n i a 2 2 3 1 4
S u p e r i n t e n d e n tAcademy o f H e a l t h S c i e n c e s , U S A r m yATTN: A H S - C O NF o r t Sam H o u s t o n , Te x a s 7 8 2 3 4
DeanSchoo l o f M e d i c i n eU n i f o r m e d S e r v i c e s U n i v e r s i t y o f t h eH e a l t h S c i e n c e sO f f i c e o f t h e S e c r e t a r y o f D e f e n s e6917 A r l i n g t o n RoadBe thesda , MD 2 0 0 1 4
![Page 23: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/23.jpg)
• I—> 0I— elo 2.)13Pla(0) 0
Ee o2-1 i n-• (1) -112 0
ac
toa•40 I Inr. 0
•040) > t • cf)•11 u)4
"1
=• sl)
S e l1/7111 a•
2 S c93 u▪ c 220. E 2 co
(I) 0) C Ore, 0 1:1 m c0
0 vt ,7
▪ .11 "Et E
= • U. • (11 C10 E• _ e cticc ill a.NI- A A
2 tij "0. ao
0 46 Z.owl 01Y,c0zNI' W w
In to 0; 0 VZ rl:
Reproduced by NIT i SNational Technical Information ServiceSpringfield, VA 22161
This report was printed specifically for your orderfrom nearly 3 million titles available in our collection.
For economy and efficiency, NTIS does not maintain stock of itsvast collection of technical reports. Rather, most documents arecustom reproduced for each order. Documents that are not inelectronic format are reproduced from master archival copiesand are the best possible reproductions available.If you have questions concerning this document or any orderyou have placed with NTIS, please call our Customer ServiceDepartment at 1-888-584-8332 or (703) 605-6050.
About NTISNTIS collects scientific, technical, engineering, and relatedbusiness information then organizes, maintains, anddisseminates that information in a variety of formats - includingelectronic download, online access, DVD, CD-ROM, magnetictape, diskette, multimedia, microfiche and paper.The NTIS collection of nearly 3 million titles includes reportsdescribing research conducted or sponsored by federalagencies and their contractors; statistical and businessinformation; U.S. military publications; multimedia trainingproducts; computer software and electronic databasesdeveloped by federal agencies; and technical reports preparedby research organizations worldwide.
For more information about NTIS, visit our Web siteat http://www.ntis“gov.
NTis
Ensuring Permanent, Easy Access toU.S. Government Information Assets
ALL SALES ARE FINAL
![Page 24: 1977 NTIS Annual Report: Phase I Clinical Testing. Antimalarial Drugs. Annual Report](https://reader031.vdocument.in/reader031/viewer/2022020222/577c81611a28abe054ac9d75/html5/thumbnails/24.jpg)
ATES Of
U.S. DEPARTMENT OF COMMERCENational Technical Information ServiceAlexandria, VA 22312 7 0 3 - 6 0 5 - 6 0 0 0